Исследования и наука

US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer

US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer BioPharma APAC

Michael Sapienza: When Cancer Research Hits a Roadblock, Innovation Finds a Way

Michael Sapienza: When Cancer Research Hits a Roadblock, Innovation Finds a Way Oncodaily

US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer

US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer biopharmaapac.com

Why Investigate Implant Upsizing in a Mastectomy Skin Flap Necrosis Study?

Sendurai Mani: Alicia Zhou’s Journey Into Cancer Research Leadership

Sendurai Mani: Alicia Zhou’s Journey Into Cancer Research Leadership Oncodaily

Valerie Chew: Advances in Liver Cancer Research at ILCA 2026

Valerie Chew: Advances in Liver Cancer Research at ILCA 2026 Oncodaily

FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models

FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models The Clinical Trial Vanguard

Dr Vineet Talwar appointed Medical Director of Rajiv Gandhi Cancer Institute and Research Centre

Dr Vineet Talwar appointed Medical Director of Rajiv Gandhi Cancer Institute and Research Centre Medical Dialogues

Y-ESSO Research Grants for Young Surgical Oncologists 2026

Y-ESSO Research Grants for Young Surgical Oncologists 2026 Oncodaily

Opioid dependence adds heavy burden for hospitalized cancer patients, study finds

Opioid dependence adds heavy burden for hospitalized cancer patients, study finds Bioengineer.org

ASCO Advocacy in Action for Cancer Research Funding

ASCO Advocacy in Action for Cancer Research Funding Oncodaily

Bob Li Highlights a Major Step Toward More Equitable Cancer Trials

Bob Li Highlights a Major Step Toward More Equitable Cancer Trials Oncodaily

Исследование: каждый дополнительный час непрерывного сидения повышает риск смерти от рака на 9%

Исследование: каждый дополнительный час непрерывного сидения повышает риск смерти от рака на 9% RuNews24

Inhibrx to Present INBRX-106 Phase 2 Data in Head and Neck Cancer Study

Inhibrx to Present INBRX-106 Phase 2 Data in Head and Neck Cancer Study The Clinical Trial Vanguard

Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal

Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal Yahoo Finance UK